What are the indications for systemic thrombolysis in acute pulmonary embolism according to the 2026 ACC/AHA guidelines?

Indications for Systemic Thrombolysis in Acute Pulmonary Embolism

Systemic thrombolysis is indicated for acute PE with hypotension (systolic BP < 90 mmHg) in patients without high bleeding risk, and should be strongly considered in hemodynamically stable patients who deteriorate on anticoagulation before developing frank hypotension. 1

Primary Indication: High-Risk (Massive) PE with Hypotension

Patients with acute PE associated with hypotension (systolic BP < 90 mmHg) who do not have a high bleeding risk should receive systemically administered thrombolytic therapy. 1, 2 This represents a weak recommendation with low-certainty evidence, but there is consensus among guideline panels to administer thrombolysis to most patients with acute PE and prolonged hypotension in the absence of contraindications. 2

• High-risk PE is defined by systolic blood pressure < 90 mmHg, requirement for vasopressors, or signs of end-organ hypoperfusion (altered mental status, cold/clammy skin, oliguria, elevated lactate). 3
• Thrombolysis should be administered without delay once the diagnosis is confirmed. 4
• The greatest benefit is observed when treatment is initiated within 48 hours of symptom onset, though thrombolysis can still be useful in patients with symptoms for 6-14 days. 4

Strong Contraindication: Hemodynamically Stable PE

In most patients with acute PE not associated with hypotension, systemic thrombolytic therapy is strongly recommended against. 1, 2 This is a strong recommendation despite low-certainty evidence, reflecting the panel's high value on avoiding potential harm when the magnitude of benefit is variable. 1

• Thrombolysis in hemodynamically stable patients has been associated with 65 more major bleeding events per 1,000 cases (including intracranial hemorrhage), with benefits and harms finely balanced and no convincing net benefit. 2
• The 2019 ESC and 2020 NICE guidelines similarly recommend against routine use of thrombolysis in hemodynamically stable patients, regardless of right ventricular dysfunction. 2

Secondary Indication: Clinical Deterioration Without Frank Hypotension

In selected patients with acute PE who deteriorate after starting anticoagulant therapy but have yet to develop hypotension and who have acceptable bleeding risk, systemic thrombolytic therapy should be considered. 1, 2 This is a weak recommendation with low-certainty evidence. 1

Criteria for Clinical Deterioration:

Patients should be monitored for the following signs of deterioration while on full anticoagulation: 2

• Decrease in systolic blood pressure
• Increase in heart rate
• Worsening gas exchange
• Signs of inadequate perfusion
• Worsening right ventricular function on echocardiography
• Increasing cardiac biomarkers (troponin, BNP)

Such deterioration should prompt consideration of thrombolytic therapy in the absence of frank shock if bleeding risk is deemed acceptable. 2

Route of Administration

When thrombolysis is indicated, systemic thrombolytic therapy via peripheral vein is preferred over catheter-directed thrombolysis (CDT). 1, 2 This is a weak recommendation with low-certainty evidence, as no randomized trials have directly compared contemporary CDT with systemic thrombolytic therapy. 2

Alternative Interventions When Systemic Thrombolysis is Contraindicated or Fails

Catheter-assisted thrombus removal should be considered in patients with acute PE associated with hypotension who have: 1, 2

1. High bleeding risk
2. Failed systemic thrombolysis
3. Shock likely to cause death before systemic thrombolysis can take effect (within hours)

This requires appropriate expertise and resources, and represents a weak recommendation with low-certainty evidence. 1, 2

Thrombolytic Agents and Dosing

The 2021 CHEST guidelines do not endorse one agent or dosing strategy over another due to lack of comparative data. 2 However, approved regimens from the 2008 ESC guidelines include: 4

• rtPA (alteplase): 100 mg over 2 hours or 0.6 mg/kg over 15 minutes (maximum 50 mg)
• Streptokinase: 250,000 IU loading dose over 30 minutes, followed by 100,000 IU/h over 12-24 hours (accelerated: 1.5 million IU over 2 hours)
• Urokinase: 4,400 IU/kg loading dose over 10 minutes, followed by 4,400 IU/kg/h over 12-24 hours (accelerated: 3 million IU over 2 hours)

Bleeding Risk Assessment

Absolute Contraindications (may become relative in life-threatening PE): 4

• Hemorrhagic stroke or stroke of unknown origin at any time
• Ischemic stroke in preceding 6 months
• Central nervous system damage or neoplasms
• Recent major trauma/surgery/head injury (within 3 weeks)
• Gastrointestinal bleeding within the last month
• Known bleeding disorder

Relative Contraindications: 4

• Transient ischemic attack in preceding 6 months
• Oral anticoagulant therapy
• Pregnancy or within 1 week postpartum
• Non-compressible punctures
• Traumatic resuscitation
• Refractory hypertension (systolic BP > 180 mmHg)
• Advanced liver disease
• Infective endocarditis
• Active peptic ulcer

Critical caveat: Contraindications considered absolute in acute myocardial infarction may become relative in immediately life-threatening high-risk PE. 4

Expected Outcomes

Thrombolysis in appropriate patients is associated with: 2

• 19 fewer recurrent PE events per 1,000 cases (7 days to 12 months)
• 20 fewer all-cause mortality events per 1,000 cases (7 days to 12 months)
• 65 more major bleeding events per 1,000 cases (including 1.8% rate of intracranial/fatal hemorrhage)

Approximately 92% of patients can be classified as responders to thrombolysis based on clinical and echocardiographic improvement within the first 36 hours. 4